featured
Cabozantinib Plus Atezolizumab vs Sorafenib for Advanced Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Lancet Haematol 2022 Jul 04;[EPub Ahead of Print], RK Kelley, L Rimassa, AL Cheng, A Kaseb, S Qin, AX Zhu, SL Chan, T Melkadze, W Sukeepaisarnjaroen, V Breder, G Verset, E Gane, I Borbath, JDG Rangel, BY Ryoo, T Makharadze, P Merle, F Benzaghou, K Banerjee, S Hazra, J Fawcett, T YauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.